ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY

被引：0
|
作者：
Hernandez, Alba [1 ]
Calera, Lourdes [1 ]
Alvarez, Maria [1 ]
Hernando, Jorge [1 ]
Torres, Irene [1 ]
Pajares, Isabel [1 ]
Madani, Julia [1 ]
Cebollero, Ana [1 ]
Anton-Torres, Antonio [1 ]
Artal, Angel [1 ]
机构：
[1] Hosp Univ Miguel Servet, Zaragoza, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
erlotinib; second line; wild-type EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.24-036
引用
收藏
页码：S1017 / S1017
页数：1
相关论文
共 50 条
  • [21] Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study
    Paz-Arez, Luis
    Serwatowski, Piotr
    Szczesna, Aleksandra
    Von Pawel, Joachim
    Toschi, Luca
    Tibor, Csoszi
    Morabito, Alessandro
    Zhang, Ling
    Shuster, Dale
    Chen, Shuquan
    Copigneaux, Catherine
    Akerley, Wallace
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1214 - S1215
  • [22] EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND CORRELATION WITH SENSITIVITY TO ERLOTINIB
    Ricciardi, S.
    Tedesco, B.
    Migliorino, M. R.
    Graziano, P.
    Leone, A.
    Di Salvia, M.
    Capodaglio, V.
    Condo, S.
    De Santis, S.
    De Marinis, F.
    EJC SUPPLEMENTS, 2008, 6 (14): : 134 - 134
  • [23] Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis
    Inno, Alessandro
    Di Noia, Vincenzo
    Martini, Maurizio
    D'Argento, Ettore
    Di Salvatore, Mariantonietta
    Arena, Vincenzo
    Schinzari, Giovanni
    Orlandi, Armando
    Larocca, Luigi Maria
    Cassano, Alessandra
    Barone, Carlo
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (02) : 513 - 520
  • [24] Safety of erlotinib in patients with metastatic non-small cell lung cancer (NSCLC) exposed to radiation therapy (RTX)
    Scheffler, M.
    Semrau, R.
    Zander, T.
    Nogova, L.
    Papachristou, I.
    Bos, M.
    Stoelben, E.
    Engel-Riedel, W.
    Wolf, J.
    ONKOLOGIE, 2011, 34 : 153 - 154
  • [25] Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients with EGFR wild-type tumors
    Braun, Eduardo
    Bonomi, Philip
    LUNG CANCER MANAGEMENT, 2014, 3 (01) : 101 - 116
  • [26] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Agatsuma, Toshihide
    Yasuo, Masanori
    Tsushima, Kenji
    Kubo, Keishi
    Eda, Seiichiro
    Kuraishi, Hiroshi
    Koyama, Shigeru
    Hachiya, Tsutomu
    Ohura, Nariaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1241 - 1246
  • [27] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Takashi Kobayashi
    Tomonobu Koizumi
    Toshihide Agatsuma
    Masanori Yasuo
    Kenji Tsushima
    Keishi Kubo
    Seiichiro Eda
    Hiroshi Kuraishi
    Shigeru Koyama
    Tsutomu Hachiya
    Nariaki Ohura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1241 - 1246
  • [28] Cost of care in EGFR mutant versus wild-type non-small cell lung cancer.
    Vusqa, Urwat Til
    Asawa, Palash
    Miller, Katherine
    Sethi, Ashish
    Rodriguez, Robin Raquel
    Friday, Andrew
    Finley, Gene Grant
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Sunitinib in Combination with Erlotinib for the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Thongprasert, Sumitra
    Govindan, Ramaswamy
    Krzakowski, Maciej
    Szczesna, Aleksandra
    Strausz, Janos
    Makhson, Anatoly
    Tye, Lesley
    Zhang, Ke
    Chao, Richard C.
    Scagliotti, Giorgio V.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S375 - S375
  • [30] ERLOTINIB AS SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ECONOMIC MODELING (EM) RESULTS
    Santos, E. A., V
    Buschinelli, C. T.
    Ferracini, M.
    Pepe, C.
    Estanislao, M.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
12345